[顺铂治疗不可切除肝细胞癌疗效的临床研究]
[Clinical study of the effect of cisplatin therapy in unresectable hepatocellular carcinoma].
作者信息
Matsuki S, Sugimoto M, Nii S, Kokubu S, Yamada N, Ishii K, Shibata H, Okabe H
机构信息
Dept. of Internal Medicine, Kitasato University School of Medicine, Kanagawa.
出版信息
Gan To Kagaku Ryoho. 1988 Jan;15(1):53-7.
Twenty-one cases of unresectable hepatocellular carcinoma (HCC), including 15 cases receiving intravenous infusion of CDDP in addition to transcatheter arterial embolization (TAE), and 6 cases receiving intraarterial infusion of CDDP in combination with sodium thiosulfate rescue (STS rescue) were studied. In the 15 cases given intravenous infusion therapy with TAE, favorable effects were observed in 33.3% of patients, and the 50% survival period was 22.5 months. In the 6 cases given intraarterial infusion, favorable effects were obtained in 66.6% of patients, but the 50% survival period was 2 months. The side effects observed most frequently were nausea and vomiting. All the other side effects observed were not so severe. These results suggest that intravenous CDDP infusion in addition to TAE is favorable, producing a life-prolongation effect.
对21例无法切除的肝细胞癌（HCC）患者进行了研究，其中15例在经导管动脉栓塞术（TAE）基础上接受顺铂静脉输注，6例接受动脉内输注顺铂联合硫代硫酸钠解救（STS解救）。在15例接受TAE联合静脉输注治疗的患者中，33.3%的患者观察到良好效果，50%生存期为22.5个月。在6例接受动脉内输注的患者中，66.6%的患者获得了良好效果，但50%生存期为2个月。最常观察到的副作用是恶心和呕吐。观察到的所有其他副作用都不那么严重。这些结果表明，TAE联合顺铂静脉输注效果良好，具有延长生命的作用。
Zotero 插件